BMS-986497 + azacitidine

BMS-986497 + azacitidine is an investigational combination therapy being evaluated for relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)[3][5][7]. BMS-986497 is a **protein degrader** that selectively targets two proteins, **GSPT1** and **CD33**, on cancer cells. Its mechanism involves inducing the degradation of these proteins, thus impairing proliferation and survival of malignant cells[3][5]. Azacitidine is a **hypomethylating agent/chemotherapy** that interferes with the growth and spread of cancer cells by incorporating into DNA and RNA, leading to cytotoxicity and DNA hypomethylation[5]. The combination is currently under investigation in a Phase I trial to determine safety, tolerability, pharmacokinetics, and efficacy for patients who have failed alternative therapies[3][5][7]. Developed by Bristol Myers Squibb, this regimen is not yet FDA approved.